TY - JOUR
T1 - Pericytes, inflammation, and diabetic retinopathy
AU - Spencer, Benjamin G.
AU - Estevez, Jose J.
AU - Liu, Ebony
AU - Craig, Jamie E.
AU - Finnie, John W.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Diabetic retinopathy (DR) is a frequent complication of diabetes mellitus, and a common cause of vision impairment and blindness in these patients, yet many aspects of its pathogenesis remain unresolved. Furthermore, current treatments are not effective in all patients, are only indicated in advanced disease, and are associated with significant adverse effects. This review describes the microvascular features of DR, and how pericyte depletion and low-grade chronic inflammation contribute to the pathogenesis of this common ophthalmic disorder. Existing, novel and investigational pharmacological strategies aimed at modulating the inflammatory component of DR and ameliorating pericyte loss to potentially improve clinical outcomes for patients with diabetic retinopathy, are discussed.
AB - Diabetic retinopathy (DR) is a frequent complication of diabetes mellitus, and a common cause of vision impairment and blindness in these patients, yet many aspects of its pathogenesis remain unresolved. Furthermore, current treatments are not effective in all patients, are only indicated in advanced disease, and are associated with significant adverse effects. This review describes the microvascular features of DR, and how pericyte depletion and low-grade chronic inflammation contribute to the pathogenesis of this common ophthalmic disorder. Existing, novel and investigational pharmacological strategies aimed at modulating the inflammatory component of DR and ameliorating pericyte loss to potentially improve clinical outcomes for patients with diabetic retinopathy, are discussed.
KW - Diabetic retinopathy
KW - Inflammation
KW - Pericytes
KW - Retina
UR - http://www.scopus.com/inward/record.url?scp=85074010097&partnerID=8YFLogxK
U2 - 10.1007/s10787-019-00647-9
DO - 10.1007/s10787-019-00647-9
M3 - Review article
C2 - 31612299
AN - SCOPUS:85074010097
SN - 0925-4692
VL - 28
SP - 697
EP - 709
JO - INFLAMMOPHARMACOLOGY
JF - INFLAMMOPHARMACOLOGY
IS - 3
ER -